BIOLl 351l BIOL351l Modulel 2:l Latestl

BIOLl 351/l BIOL351l Modulel 2:l (Latestl

2026/l 2027l Update)l 100%l Verifiedl Questionsl &l Answersl |l Gradel A

Q:l Whichl onel ofl thel followingl H2l receptorsl blockersl hasl al higherl riskl ofl drugl interactions?

Answer:

b.l cimetidinel (Tagamet)

Q:l Whichl acidl controllingl drugl classl isl availablel inl manyl dosagel forms?

Answer:

a.l antacids

Q:l Whatl arel thel threel categoriesl forl OTCl status?

Answer:

1.)l Indicationsl forl Use 2.)l Safetyl Profile 3.)l Practicalityl forl OTCl use

Q:l Forl whichl conditionsl orl comorbiditiesl canl OTCl medicationsl bel

consideredl risky?

• / 3

Answer:

-l glaucoma -l cardiovascularl disease -l diabetes -l hypertension

Q:l Truel orl False:l Inl mostl cases,l OTCl medicationsl arel simplyl treatingl symptomsl andl arel notl gettingl tol thel causel ofl thel problem

Answer:

True

Q:l Ifl al patientl isl takingl tranquilizersl orl sedatives,l shouldl theyl takel anl OTCl medicationsl suchl asl anl antihistamine,l whyl orl whyl not?

Answer:

No,l becausel antihistaminesl canl makel youl sleepyl andl thisl couldl bel problematic

Q:l Whyl isl itl importantl tol payl attentionl tol thel inactivel ingredientsl onl al drugl factsl label?

Answer:

Becausel itl couldl containl anl ingredientl thatl al personl isl allergicl tol (e.g.l lactose)l andl causel unwantedl allergicl reactions

Q:l Ifl someonel hasl highl bloodl pressure,l forl whichl OTCl medicationl mightl theyl wantl tol bel cautiousl aboutl &l why? 2 / 3

Answer:

Theyl mightl wantl tol bel cautiousl aboutl al nasall decongestantl becausel itl canl constrictl thel bloodl vesselsl andl leadl tol anl increasel inl bloodl pressure

Q:l Whichl factorl determinesl whetherl thel therapeuticl effectl isl goingl tol bel different?

Answer:

Dependentl onl ifl thel drugl isl targetingl anl H1l orl H2l receptor

Q:l Whichl dietaryl supplementl isl thel onlyl onel thatl isl FDAl approvedl andl hasl al prescription?l Whatl isl itl commonlyl usedl for?

Answer:

Omegal 3-Fattyl acidsl ;l cholesteroll reduction

Q:l Definel goodl manufacturingl practices

Answer:

Thisl meansl thatl forl thel firstl time,l manufacturersl wouldl bel requiredl tol providel datal demonstratingl productl identity,l composition,l purity,l andl strengthl ofl activel ingredients.

Q:l Ifl youl werel helpingl someonel selectl anl appropriatel OTCl medicationl

totreatl theirl coldl symptomsl ofl al runnyl nosel andl sneezingl whatl typel ofmedicationl wouldl youl wantl tol select?

• / 3